{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:53:08Z","timestamp":1787169188593,"version":"build-2736575974"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Boehringer Ingelheim, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Two studies were conducted assessing the efficacy of NexGard\u00ae PLUS (NP) in preventing heartworm disease. Study 1 evaluated the efficacy of six monthly doses of NP or Simparica Trio\u00ae (ST) against a macrocyclic lactone-resistant isolate of heartworm,\n                      <jats:italic>Dirofilaria immitis<\/jats:italic>\n                      , and study 2 evaluated the efficacy of a single dose of NP against a susceptible isolate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In two studies, dogs that were negative for heartworms by antigen test and modified Knott\u2019s test were used. In study 1, dogs were randomly allocated into three treatment groups (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096\/group): negative control, NP per label instructions, and ST per label instructions. Dogs were inoculated with 50 third-stage\n                      <jats:italic>D. immitis<\/jats:italic>\n                      larvae (JYD-34 isolate) on day \u221230. NP and ST were administered orally on days 0, 30, 60, 90, 120, and 150. A necropsy was performed on day 180 for adult heartworm recovery. In study 2, dogs were randomly allocated into two treatment groups (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910\/group): negative control and NP. Dogs were inoculated with 50 third-stage larvae (SC-20 isolate) on day \u221230. NP was administered orally once on day 0 to target the minimum moxidectin label dose. A necropsy was performed on day 120 for adult heartworm recovery.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      For study 1, all control dogs had adult heartworms at necropsy (geometric mean, 39.7; range, 28\u201348). Two of the NP-treated dogs had one live worm, and one of the ST-treated dogs had one live worm. Both treated groups were significantly different from the control group with an efficacy of 99.5% for NP and 99.8% for ST (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001). There was no significant difference (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.8797) between the groups treated with NP and ST. For study 2, all control dogs had adult heartworms (geometric mean, 34.5; range 26\u201343). None of the dogs treated with NP had live adult worms (efficacy of 100%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The results of study 1 demonstrated that NexGard\u00ae PLUS and Simparica Trio\u00ae administered at the label dose provided comparable efficacy against a macrocyclic lactone-resistant isolate of\n                      <jats:italic>D. immitis.<\/jats:italic>\n                      The results of study 2 demonstrated that NexGard\u00ae PLUS administered once near the minimum label dose was 100% effective against a susceptible isolate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13071-024-06603-z","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T13:11:59Z","timestamp":1734527519000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Preventive efficacy of six monthly doses of NexGard\u00ae PLUS or Simparica Trio\u00ae against a macrocyclic lactone-resistant isolate (JYD-34) of Dirofilaria immitis and of a single dose of NexGard PLUS against a susceptible isolate"],"prefix":"10.1186","volume":"17","author":[{"given":"Joseph","family":"Prullage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utami","family":"DiCosty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricarda","family":"S\u00fcssenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"6603_CR1","unstructured":"Scoles G. Vectors of canine heartworm in the United States: a review of the literature including new data from Indiana, Florida, and Louisiana, recent advances in heartworm disease: symposium\u201998. In: Proceedings of the American Heartworm Society. Tampa: American Heartworm Society; 1998. p. 21\u201336."},{"key":"6603_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1053\/j.tcam.2011.09.005","volume":"26","author":"N Ledesma","year":"2011","unstructured":"Ledesma N, Harrington L. Mosquito vectors of dog heartworm in the United States: vector status and factors influencing transmission efficiency. Top Companion Anim Med. 2011;26:178\u201385. https:\/\/doi.org\/10.1053\/j.tcam.2011.09.005.","journal-title":"Top Companion Anim Med"},{"key":"6603_CR3","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1186\/s13071-016-1804-y","volume":"9","author":"DD Bowman","year":"2016","unstructured":"Bowman DD, Liu Y, McMahan CS, Nordone SK, Yabsley MJ, Lund RB. Forecasting United States heartworm Dirofilaria immitis prevalence in dogs. Parasit Vectors. 2016;9:540. https:\/\/doi.org\/10.1186\/s13071-016-1804-y.","journal-title":"Parasit Vectors"},{"key":"6603_CR4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s13071-019-3633-2","volume":"12","author":"SW Self","year":"2019","unstructured":"Self SW, Pulaski CN, McMahan CS, Brown DA, Yabsley MJ, Gettings JR. Regional and local temporal trends in the prevalence of canine heartworm infection in the contiguous United States: 2012\u20132018. Parasit Vectors. 2019;12:380. https:\/\/doi.org\/10.1186\/s13071-019-3633-2.","journal-title":"Parasit Vectors"},{"key":"6603_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ijpddr.2021.03.004","volume":"16","author":"S Noack","year":"2021","unstructured":"Noack S, Harrington J, Carithers DS, Kaminsky R, Selzer PM. Heartworm disease\u2014overview, intervention, and industry perspective. Int J Parasitol Drugs Drug Resist. 2021;16:65\u201389. https:\/\/doi.org\/10.1016\/j.ijpddr.2021.03.004.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"6603_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.vetpar.2011.01.023","volume":"176","author":"C Bourguinat","year":"2011","unstructured":"Bourguinat C, Keller K, Prichard RK, Geary TG. Genetic polymorphism in Dirofilaria immitis. Vet Parasitol. 2011;176:368\u201373. https:\/\/doi.org\/10.1016\/j.vetpar.2011.01.023.","journal-title":"Vet Parasitol"},{"key":"6603_CR7","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1186\/s13071-014-0494-6","volume":"7","author":"CN Pulaski","year":"2014","unstructured":"Pulaski CN, Malone JB, Bourguinat C, Prichard R, Geary T, Ward D, et\u00a0al. Establishment of macrocyclic lactone resistant Dirofilaria immitis isolates in experimentally infected laboratory dogs. Parasit Vectors. 2014;7:494. https:\/\/doi.org\/10.1186\/s13071-014-0494-6.","journal-title":"Parasit Vectors"},{"key":"6603_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13071-016-1476-7","volume":"9","author":"BL Blagburn","year":"2016","unstructured":"Blagburn BL, Arther RG, Dillon AR, Butler JM, Bowles JV, von Simson C, et\u00a0al. Efficacy of four commercially available heartworm preventive products against the JYD-34 laboratory strain of Dirofilaria immitis. Parasit Vectors. 2016;9:191. https:\/\/doi.org\/10.1186\/s13071-016-1476-7.","journal-title":"Parasit Vectors"},{"key":"6603_CR9","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1186\/s13071-017-2431-y","volume":"10","author":"DD Bowman","year":"2017","unstructured":"Bowman DD, McTier TL, Adams EL, Magabir SP, Login JA, Bidgood T, et\u00a0al. Evaluation of the efficacy of ProHeart\u00ae 6 (moxidectin) against a resistant isolate of Dirofilaria immitis (JYD-34) in dogs. Parasit Vectors. 2017;10:502. https:\/\/doi.org\/10.1186\/s13071-017-2431-y.","journal-title":"Parasit Vectors"},{"key":"6603_CR10","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s13071-017-2429-5","volume":"10","author":"TL McTier","year":"2017","unstructured":"McTier TL, Six RH, Pullins A, Chapin S, McCall JW, Rugg D, et\u00a0al. Efficacy of oral moxidectin against susceptible and resistant isolates of Dirofilaria immitis in dogs. Parasit Vectors. 2017;10:482. https:\/\/doi.org\/10.1186\/s13071-017-2429-5.","journal-title":"Parasit Vectors"},{"key":"6603_CR11","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s13071-019-3685-3","volume":"12","author":"TL McTier","year":"2019","unstructured":"McTier TL, Six RH, Pullins A, Chapin S, Kryda K, Mahabir SP, et\u00a0al. Preventive efficacy of oral moxidectin at various doses and dosage regimens against macrocyclic lactone-resistant heartworm (Dirofilaria immitis) strains in dogs. Parasit Vectors. 2019;12:444. https:\/\/doi.org\/10.1186\/s13071-019-3685-3.","journal-title":"Parasit Vectors"},{"key":"6603_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s13071-020-04178-z","volume":"13","author":"K Kryda","year":"2020","unstructured":"Kryda K, Holzmer SJ, Everett WR, McCall JW, Mahabir SP, McTier TL, et\u00a0al. Preventive efficacy of four or six monthly oral doses of 24 \u03bcg\/kg moxidectin compared to six monthly doses of Heartgard\u00ae PLUS or Interceptor\u00ae PLUS against macrocyclic lactone-resistant heartworm (Dirofilaria immitis) strains in dogs. Parasit Vectors. 2020;13:339. https:\/\/doi.org\/10.1186\/s13071-020-04178-z.","journal-title":"Parasit Vectors"},{"key":"6603_CR13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13071-024-06149-0","volume":"17","author":"EM Martin","year":"2024","unstructured":"Martin EM, Mitchell EB, Yoon S, McCall JW, Fankhauser B, Mansour A, et\u00a0al. Efficacy of moxidectin, using various dose regimens, against JYD-34, a macrocyclic lactone resistant isolate of Dirofilaria immitis. Parasit Vectors. 2024;17:176. https:\/\/doi.org\/10.1186\/s13071-024-06149-0.","journal-title":"Parasit Vectors"},{"key":"6603_CR14","unstructured":"McTier TL, McCall JW, Dzimianski MT, Aguilar R, Wood I. Prevention of experimental infection in dogs with single, oral doses of moxidectin. In: Proceedings of the Heartworm Symposium \u02bc92. Batavia: American Heartworm Society; 1992. p. 165\u20138."},{"key":"6603_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijpddr.2019.06.002","volume":"10","author":"RK Prichard","year":"2019","unstructured":"Prichard RK, Geary TG. Perspectives on the utility of moxidectin for the control of parasitic nematodes in the face of developing anthelmintic resistance. Int J Parasitol Drugs Drug Resist. 2019;10:69\u201383. https:\/\/doi.org\/10.1016\/j.ijpddr.2019.06.002.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"6603_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13071-021-05104-7","volume":"15","author":"MD Savadelis","year":"2022","unstructured":"Savadelis MD, McTier TL, Kryda K, Maeder SJ, Woods DJ. Moxidectin: heartworm disease prevention in dogs in the face of emerging macrocyclic lactone resistance. Parasit Vectors. 2022;15:82. https:\/\/doi.org\/10.1186\/s13071-021-05104-7.","journal-title":"Parasit Vectors"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-024-06603-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-024-06603-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-024-06603-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T14:03:38Z","timestamp":1734530618000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-024-06603-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6603"],"URL":"https:\/\/doi.org\/10.1186\/s13071-024-06603-z","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"30 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted under the direction of Boehringer Ingelheim, and the protocol was approved by the appropriate animal welfare committees or governing authorities. These studies were run under an IACUC (Independent Animal Care and Use Committee) approval number of APS 22-201. The study was conducted according to state and national regulations regarding animal welfare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.P., J.F., E.M., P.D., S.Y., and R.S. are all current employees of Boehringer Ingelheim. U.D. is a contracted parasitologist\/study investigator. Other than that, the authors declare no conflict of interest. This document is provided for scientific purposes only.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"519"}}